Literature DB >> 26057953

First oncolytic virus edges towards approval in surprise vote.

Cormac Sheridan.   

Abstract

Mesh：

Year:  2015        PMID： 26057953     DOI： 10.1038/nbt0615-569

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors:  Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956
  1 in total
  13 in total

Review 1.  The changing landscape of clinical trial and approval processes in China.

Authors:  Qing Zhou; Xiao-Yuan Chen; Zhi-Min Yang; Yi-Long Wu
Journal:  Nat Rev Clin Oncol       Date:  2017-02-14       Impact factor: 66.675

2.  Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.

Authors:  Hong Jiang; Dong Ho Shin; Teresa T Nguyen; Juan Fueyo; Xuejun Fan; Verlene Henry; Caroline C Carrillo; Yanhua Yi; Marta M Alonso; Tiara L Collier; Ying Yuan; Frederick F Lang; Candelaria Gomez-Manzano
Journal:  Clin Cancer Res       Date:  2019-08-27       Impact factor: 12.531

3.  Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.

Authors:  Hong Jiang; Yisel Rivera-Molina; Candelaria Gomez-Manzano; Karen Clise-Dwyer; Laura Bover; Luis M Vence; Ying Yuan; Frederick F Lang; Carlo Toniatti; Mohammad B Hossain; Juan Fueyo
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

4.  Cancer targeted therapeutics: From molecules to drug delivery vehicles.

Authors:  Daxing Liu; Debra T Auguste
Journal:  J Control Release       Date:  2015-09-02       Impact factor: 9.776

Review 5.  Viral oncolytic immunotherapy in the war on cancer: Infection control considerations.

Authors:  Elizabeth V Robilotti; Asmita Kumar; Michael S Glickman; Mini Kamboj
Journal:  Infect Control Hosp Epidemiol       Date:  2019-02-15       Impact factor: 3.254

6.  A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy.

Authors:  Han Hu; Siqi Zhang; Linkang Cai; Haixiao Duan; Yuying Li; Junhan Yang; Yang Wang; Biao Liu; Shuang Dong; Zhizheng Fang; Binlei Liu
Journal:  Virol J       Date:  2022-04-22       Impact factor: 5.913

7.  The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.

Authors:  Carmela Passaro; Francesco Borriello; Viviana Vastolo; Sarah Di Somma; Eloise Scamardella; Vincenzo Gigantino; Renato Franco; Gianni Marone; Giuseppe Portella
Journal:  Oncotarget       Date:  2016-01-12

Review 8.  Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.

Authors:  Guy Ungerechts; Sascha Bossow; Barbara Leuchs; Per S Holm; Jean Rommelaere; Matt Coffey; Rob Coffin; John Bell; Dirk M Nettelbeck
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-06       Impact factor: 6.698

Review 9.  Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.

Authors:  Huitao Liu; Honglin Luo
Journal:  Viruses       Date:  2021-06-05       Impact factor: 5.048

10.  AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.

Authors:  Maria Victoria Maliandi; Ana Mato-Berciano; Luciano Sobrevals; Gaël Roué; Anabel José; Cristina Fillat
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.